What is autism, and how do we make a diagnosis in the new era of DSM-5 and ICD-11; Assessment and treatment of common mental health problems in autistic people
In this presentation, Dr Whitwell provides an overview of the process of making a diagnosis of autism with a focus on adult presentations. There has been a big change in how the general public and the medical profession perceives neurodevelopmental disorders and clinical practice and this has implications for diagnostic assessment. The presentation will review changes from ICD-10 and DSM-IV to ICD-11 and DSM-5 and highlights some of the challenges of diagnostic assessment in this population.
Sex differences in neurodevelopmental disorders; Autism, psychopathy and empathy
Impairments of empathy are features of autism spectrum disorder (ASD) and some personality disorders, including the severe personality disorder of psychopathy, and this talk considers the clinical and cognitive neuroscience perspectives. The aim is to show how improved understanding of the components of empathy can assist assessment, diagnosis, formulation and management of autistic people and people with personality disorder respectively.
Developing psychological interventions for autistic adults
Historically, autistic adults have been denied access to psychological interventions. This presentation will describe the wide range of psychological interventions that are now successfully offered to this client group, as well as exploring the barriers autistic people experience trying to access these interventions and how to overcome these barriers.
Developing psychological interventions for autistic children
This presentation will aim to provide a brief overview of current NICE guidelines on psychological interventions for autistic children and adolescents, a background on the evidence base for individual, family and network interventions and the common therapeutic adaptations required when working with this population.
Autism, causes and treatments – where are we now; Pharmacological treatments of ASD – research initiatives
There have been very few highly effective new drug treatments developed in psychiatry over the last decade. This presentation will discuss why that is, and the progress that is being made in one exemplar condition by an EU Network. The lessons learnt from this work are likely of relevance to a wide range of others.
Prices:
| Non-member fee |
£106 |
| Consultant fee |
£79.50 |
| SAS doctor/Higher trainee fee |
£58.30 |
| Core trainee/Subsidised/Retired/Medical student/Foundation doctor |
£37.10 |
